Ganaxolone trial for babies and toddlers with CDKL5 seizures
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests ganaxolone, a seizure medicine, to see if it can reduce seizures in young children with CDKL5 deficiency. Participants get the real medicine or a placebo, and families help track seizures every day.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child has a confirmed CDKL5 diagnosis with a likely disease-causing gene change
- Child is 6 months to under 2 years old
- Seizures have not been controlled despite trying one or more anti-seizure medicines at the right doses
- In the 28 days before screening, the child had at least 8 countable seizures (with clear movement)
- Seizure medicines are stable for at least 2 weeks, and doses won’t be changed during the main blinded part
- Caregiver can keep accurate daily seizure log entries and give study medicine with food three times daily
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether daily warm baths at home can help reduce seizures in children with CDKL5 deficiency disorder—a rare genetic condition that causes hard-to-control epilepsy. The study wants to see if heat therapy is safe and actually works for these children.
This study is for anyone diagnosed with CDKL5 disorder who can be seen at participating clinics or is already listed in an international CDKL5 registry. The goal is to help researchers better understand the condition and support future research.
This study tests whether changing the gut environment can help reduce seizures in children and adults with CDKL5 deficiency disorder, a rare genetic condition that causes hard-to-control seizures. It is designed for people whose seizures aren't controlled by medicine and who do not have other gut issues or special diets.
This study tests whether a medication called ganaxolone can reduce irritability and aggressive behaviors in children ages 5–17 with autism. Ganaxolone works on the brain in a way that may help calm emotional outbursts and frustration.
This study looks at switching children with Dravet or Lennox Gastaut syndrome from artisanal CBD products to a standardized FDA-approved CBD medication called Epidiolex, to see if it works as well or better for seizure control.
This study tests a new medicine (S230815) given by lumbar puncture (spinal tap) to see if it helps reduce seizures in children with a specific genetic cause of epilepsy. It is for children aged 2 to 12 who have not responded well to other treatments.
Hear when a new CDKL5 Deficiency Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.